Arrowhead Pharmaceuticals Presented Interim Data From Phase 2 Gateway Study Of ARO-ANG3 For Homozygous Familial Hypercholesterolemia, Demonstrating 44-48% Mean Reductions In LDL-C Achieved On Top Of Continued Standard Of Care; Phase 3 Planning Is Ongoing
Portfolio Pulse from Benzinga Newsdesk
Arrowhead Pharmaceuticals presented interim data from its Phase 2 Gateway study of ARO-ANG3 for homozygous familial hypercholesterolemia, showing 44-48% mean reductions in LDL-C. The company is planning a Phase 3 study and intends to meet with regulatory authorities in H2 2023.
May 23, 2023 | 11:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arrowhead Pharmaceuticals' ARO-ANG3 demonstrated promising results in Phase 2 study, with plans for Phase 3 study and regulatory meetings in H2 2023.
The positive interim data from the Phase 2 study of ARO-ANG3 indicates potential for the drug's success in treating homozygous familial hypercholesterolemia. The company's plans for a Phase 3 study and regulatory meetings in H2 2023 show progress in the drug's development, which could positively impact Arrowhead Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100